

Company Focus

SMALL & MID CAP

30 January 2009 | 14 pages

Thermax (THMX.BO)

Outlook Remains Challenging. Cutting TP to Rs211

- Better than expected results Standalone PAT up 9% YoY Revenues declined by 6%YoY, led by a decline of 9%YoY in the energy segment. Environment segment grew by 14%YoY. Margins (adjusted for forex loss) have improved by 137bps, driven by cost cutting initiatives. Order book of Rs41bn is up 40%YoY; however, the pace of order book growth has moderated.
- Pushback in investments to hurt order inflows Management suggested there is "substantial resistance" from clients to finalize orders, especially large sized projects. Some clients have cancelled/slowed execution. According to Thermax, cement and metals sector capex is expected to slow down while the power sector will continue to invest, albeit at a lower level than before.
- But there are some positives 1) While risks to order inflows remain, we believe increased power sector exposure should help provide some support to growth. 2) Mgmt has been ahead of the curve and seems geared to handle the downturn; ~293bps margin improvement for 9MFY09 is commendable, esp. since it was in the back-drop of rising input costs & no pass through clauses.
 3) The company has no debt and one of the highest RoEs in the sector.
- Cutting ests by 23%-31% for FY10-11E, TP to Rs211. Maintain Buy We cut our rev assumptions to factor in moderating growth trajectory. We cut our TP to Rs211 (from Rs480) based on 8x FY10E (15x Dec09E earlier). We value Thermax at 50% discount to BHEL given its lower visibility and earnings growth. Historically Thermax has traded on par with BHEL, but in recent past, has been trading at widening discount. We raise our risk rating to Medium from Low reflecting the difficult environment for private sector capex.

Figure 1. Thermax Statistical Abstract

Year to	Net Profit	Diluted El EPS	PS growth	P/E	P/B	ROE	Yield
31-Mar	(RsM)	(Rs)	(%)	(x)	(x)	(%)	(%)
2007A	1,992	16.72	96.1%	9.5	3.2	38.0%	3.8%
2008A	2,886	24.22	44.9%	6.6	2.5	42.9%	3.8%
2009E	3,068	25.75	6.3%	6.2	2.1	37.2%	5.0%
2010E	3,139	26.35	2.3%	6.0	1.7	31.5%	5.0%
2011E	3,469	29.11	10.5%	5.5	1.5	28.8%	6.3%


Source: Company reports, Citi Investment Research

See Appendix A-1 for Analyst Certification and important disclosures.

Rating change Target price change Estimate change Results

Buy/Medium Risk	1 M
from Buy/Low Risk	
Price (29 Jan 09)	Rs159.30
Target price	Rs211.00
from Rs480.00	
Expected share price return	32.5%
Expected dividend yield	5.0%
Expected total return	37.5%
Market Cap	Rs18,982M
	US\$390M

Price Performance (RIC: THMX.BO, BB: TMX IN)



Deepal Delivala¹

+91-22-6631-9857 deepal.delivala@citi.com

Venkatesh Balasubramaniam¹

+91-22-6631-9864

venkatesh.balasubramaniam@citi.com

Atul Tiwari¹

+91-22-6631-9866 atul.tiwari@citi.com

Citi Investment Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Non-US research analysts who have prepared this report are not registered/qualified as research analysts with the NYSE and/or NASD. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. ¹Citigroup Global Markets India Private Limited

Fiscal year end 31-Mar	2007	2008	2009E	2010E	2011E
Valuation Ratios					
P/E adjusted (x)	9.5	6.6	6.2	6.0	5.5
EV/EBITDA adjusted (x)	4.8	3.1	3.2	3.1	2.4
P/BV (x)	3.2	2.5	2.1	1.7	1.5
Dividend yield (%)	3.8	3.8	5.0	5.0	6.3
Per Share Data (Rs)					
EPS adjusted	16.72	24.22	25.75	26.35	29.11
EPS reported	16.26	24.40	19.94	26.35	29.11
BVPS	49.50	63.41	74.96	92.15	109.81
DPS	6.00	6.00	8.00	8.00	10.00
Profit & Loss (RsM)					
Net sales	23,266	34,815	33,783	36,459	39,925
Operating expenses	-20,573	-30,781	-29,464	-32,085	-35,112
EBIT	2,694	4,035	4,318	4,374	4,812
Net interest expense	-15	-17	-22	-22	-22
Non-operating/exceptionals	360	439	351	404	464
Pre-tax profit	3,038	4,457	4,648	4,756	5,255
Тах	-1,046	-1,571	-1,580	-1,616	-1,786
Extraord./Min.Int./Pref.div.	-55	21	-692	0	0
Reported net income	1,937	2,907	2,376	3,139	3,469
Adjusted earnings	1,992	2,886	3,068	3,139	3,469
Adjusted EBITDA	2,889	4,267	4,628	4,740	5,190
Growth Rates (%)	40.1	40.0		7.0	0.5
Sales	43.1	49.6	-3.0	7.9	9.5
EBIT adjusted	67.6	49.8	7.0	1.3	10.0
EBITDA adjusted EPS adjusted	63.4 96.1	47.7 44.9	8.5 6.3	2.4 2.3	9.5 10.5
	50.1	-++.J	0.0	2.5	10.5
Cash Flow (RsM)	0 401	0.007	407	0 504	0.470
Operating cash flow	3,421	2,667	487	3,584	3,470
Depreciation/amortization Net working capital	195 1,313	232 -538	310 -2,199	366 79	378 -376
Investing cash flow	-2,317	-558 - 1,242	-2,199 330	- 200	-370 -200
Capital expenditure	-545	-1,382	-1,670	-200	-200
Acquisitions/disposals	-1,772	140	2,000	0	0
Financing cash flow	-679	-1,271	-999	-1,091	-1,364
Borrowings	-48	-22	0	0	0
Dividends paid	-825	-1,115	-1,091	-1,091	-1,364
Change in cash	425	154	-182	2,292	1,906
Balance Sheet (RsM)					
Total assets	17,766	20,278	21,104	24,014	26,852
Cash & cash equivalent	972	1,127	944	3,237	5,143
Accounts receivable	4,000	5,305	6,386	6,892	7,657
Net fixed assets	1,789	2,939	4,299	4,133	3,955
Total liabilities	11,868	12,722	12,171	13,034	13,768
Accounts payable	3,117	4,552	4,069	4,405	4,824
Total Debt	22	0	0	0	0
Shareholders' funds	5,898	7,556	8,932	10,980	13,084
Profitability/Solvency Ratios (%)					
EBITDA margin adjusted	12.4	12.3	13.7	13.0	13.0
ROE adjusted	38.0	42.9	37.2	31.5	28.8
ROIC adjusted	176.9	148.6	59.2	45.4	48.7
Net debt to equity	-16.1	-14.9	-10.6	-29.5	-39.3
Total debt to capital	0.4	0.0	0.0	0.0	0.0

For further data queries on Citi's full coverage universe please contact CIR Data Services Asia Pacific at CIRDataServicesAsiaPacific@citi.com or +852-2501-2791



Q309 results review

Standalone results – Revenues for Thermax declined by 6%YoY, led by a decline of 9%YoY in energy segment revenues. Environment segment clocked a decent growth of 14%YoY. Margins (adjusted for forex loss) have improved by 137bps, driven by productivity improvement and cost cutting initiatives. Recurring PAT grew by 9%YoY. The company reported an order book of Rs41bn, up 40%YoY.

Figure 2. Thermax Standalone Results (RsM, percent)

	3QFY08	3QFY09E
Sales & Services (excluding Excise Duty)	8,343	7,880
Other Income from Operations	111	71
Total Income	8,454	7,951
% Growth YoY		-6%
EBITDA	1,026	1,074
EBITDA margin%	12.1%	13.5%
Change bps		137
Depreciation	(53)	(84)
Interest	(3)	(6)
Other Income	86	88
PBT	1,056	1,072
Тах	(323)	(275)
Effective Tax rate %	31%	26%
Recurring PAT	734	797
Recurring PAT margin %	9%	10%
Recurring PAT growth %		9%
Forex gain/ losses	17	(74)
Reported PAT	750	723

Source: Company reports, Citi Investment Research

Conference Call Takeaways

- Revenues in the quarter declined because of a conscious effort by the company to scale back execution for certain projects where it is sensing clients to be under funding constraint. This is to prevent working capital build-up at Thermax.
- Order inflows and outlook Given the tight liquidity environment, Thermax is sensing "substantial resistance" from clients to finalize orders, especially large sized projects. If the current environment continues, it expects projects to be executed at a slower pace. There have been order cancellations, not too large, but some of these clients are now resuming discussions given that input costs have dropped.
- Who is investing and who is not The top 4 client segments for Thermax for 9MFY09 have been Power, Metals, Refineries and Cement. The company expects significant slowdown in investments in the cement and metals sector. It expects power sector to continue to invest, albeit at a lower level than before. Pharmaceutical and food processing are also expected to continue investments; however, these would not be extensive in nature and the demand would be more for packaged /product boilers.

 Margins have expanded because of productivity improvement and cost cutting initiatives across the company. Thermax expects margins to be maintained at current levels.

Cutting Estimates by 23%-31% over FY10E-11E

We are cutting our estimates for FY10E -11E by 23%-31% on the back of a 28%-36% cut in revenues over the same period. Our margin assumptions have gone up a bit, given that the company should show a sharp improvement in margins on the back of cost-cutting initiatives. For FY09E, while our revenue assumptions have declined by 18%, it is compensated by an increase in margin assumptions by 270bps. We now expect Thermax to post earnings CAGR of 6% over FY09-11E.

Figure 3. Thermax estimate change (RsM, percent)


	FY09E	FY10E	FY11E
Sales			
Old	41,323	50,724	62,668
New	33,783	36,459	39,925
% change	-18%	-28%	-36%
EBITDA margins			
Old	11.00%	12.00%	12.00%
New	13.70%	13.00%	13.00%
bps change	270	100	100
PAT			
Old	3,067	4,062	5,057
New	3,068	3,139	3,469
% change	0%	-23%	-31%

Source: Citi Investment Research

Cutting target price to Rs211

We now value Thermax at Rs211 based on 8x FY10E vs. 15x Dec09E earlier. Historically, Thermax has traded almost on par with BHEL. However, in the recent past, it has started to trade at a widening discount, which is understandably so – in a downcycle, BHEL with higher visibility deserves to trade at a premium, in our view. We now value Thermax at a 50% discount to BHEL vs. a 25% discount earlier given its lower visibility and earnings growth.

Figure 4. Thermax vs BHEL PE



Source: Citi Investment Research

Why still a Buy

- Outlook remains challenging, but power sector should provide some support to growth- Exposure to private sector capex makes Thermax vulnerable to delays /cancellation of orders. Given the overall tight environment, companies have pulled back investment outlays and this will have an impact on the order inflows for the company. While the risks to order inflows remain, we believe that increased power sector/ utility boiler exposure would help provide some support to growth.
- Management seems geared to handle downturn Thermax management has been one of the first in the sector to recognize the slowdown and has taken appropriate steps to deal with it. The company has undertaken a lot of cost cutting and productivity improvement evident in ~293bps margin improvement for 9MFY09. This improvement was in the back-drop of rising input costs and no pass through clauses. In the unwinding of the capex cycle, we believe the risk of negative surprises by the company is relatively lower than other companies in our capital goods/construction space. Management has curtailed capex and is in a cash conservation mode.
- Despite the cut in our earnings, the company continues to have one of the highest RoE's in the capital goods sector.


Figure 5. Capital Goods RoE's

	FY07	FY08	FY09E	FY10E	FY11E
BHEL (1L, BHEL.BO)	31%	27%	27%	32%	30%
Areva (3M, AREV.BO)	43%	47%	39%	34%	34%
ABB (3L, ABB.BO)	33%	35%	29%	28%	26%
L&T (2L, LART.BO)	27%	26%	23%	21%	20%
Thermax (1M, THMX.BO)	38%	43%	37%	32%	29%

Source: Citi Investment Research

Figure 6. Thermax PE chart

Figure 7. Thermax – Relative performance vs Sensex and BHEL



Thermax

Company description

Thermax specializes in energy and environment engineering solutions. It offers products and services in heating, cooling, waste heat recovery, captive power, water treatment and recycling, waste management and performance chemicals

Investment strategy

We have a Buy / Medium Risk (1M) rating on Thermax shares. Our rating is supported by our forecast FD EPS CAGR of 6% for FY09E-11E and ROEs of ~28-37%. Thermax has a 21% share in the overall boiler market in India, and is the leader in small and medium-sized boilers. BHEL, with a 69% market share, is the industry's only other scale player. With BHEL focusing on higher-capacity utility boilers, Thermax appears poised to capture a larger share of market in industrial boilers and smaller-capacity utility boilers. We think Thermax is in a sweet spot given 1) India's captive power capacity is set to grow by 63% in the next five years due to lack of quality supply and high industrial tariffs; and 2) higher environmental standards would increase demand for its products.

Valuation

Our target price for Thermax shares of Rs211 is based on a target P/E multiple of 8x Mar-10E, at a 50% discount to our 16x target multiple for BHEL. We believe Thermax should trade at a discount to BHEL given that BHEL is the market leader and is a direct beneficiary of all power capex in India, and the fact that Thermax has lower visibility of revenues as compared to BHEL.

Risks

We rate Thermax shares as Medium Risk. We have raised our risk rating to Medium from Low given Thermax's business model is dependent on capex of the private sector, which is currently facing higher interest rate environment and liquidity constraints. The key downside risks that could prevent the shares from reaching our target price include: lower than expected order inflows, rising interest rates, rupee appreciation, manpower shortages, increasing competition, decline in oil prices, low pricing flexibility, international operations and a pending lawsuit in US.

Bharat Heavy (BHEL.BO; Rs1,355.70; 1L)

Valuation

Our target price of Rs1,373 is based on a target P/E multiple of 16x, which is set at a ~13% discount to the historical average P/E multiple given the global credit crisis and the de-rating of most stocks globally. Our target multiple is well supported by EPS CAGR of 27% over FY08-FY11E with average RoEs at 29%. Our target multiple is set at 14% premium to ABB given BHEL's superior earnings growth expectations vis-à-vis ABB (18%) and in line L&T given more or less similar earnings growth expectations (23%).

Risks

We rate BHEL Low Risk in line with our quantitative risk-rating system, which tracks 260-day historical share price volatility. We believe BHEL deserves a Low Risk rating as its order book provides good earnings visibility over the medium term. Key downside risks to the stock achieving our target price are: 1) Delays in power-sector reforms could affect order flows and earnings; 2) Regulatory uncertainties could hurt valuations and the sentiment toward the stock; 3) Competitive pressures from global majors are a concern, particularly as technology upgrades are affected; and 4) In the short-term, progress on order flows would influence market sentiment.

Areva T & D India (AREV.BO; Rs178.95; 3M) Valuation

Our target price of Rs167 is based on a target P/E multiple of 14x CY09E. Our target P/E multiple is in line with that of ABB. Though Areva T&D's expected EPS CAGR/ RoEs over CY08E -10E at 19%/ 36% are superior to that of ABB at 18%/ 27%, we do not accord a premium to Areva T&D given ABB's superior leverage and FCF profile. Our target P/E multiple is also set at a discount to the historical average P/E multiple given the global credit crisis and the subsequent de-rating of stocks.

As reference, our target multiple for ABB is derived using the historical average PEG of 0.8 and our expectations of 18% EPS CAGR to arrive at a target P/E multiple of 14x.

Risks

Our quantitative risk-rating system, which tracks 260-day historical share price volatility, assigns a High Risk rating to Areva T&D India. However, we believe a Medium Risk rating is more appropriate given that strong power and industrial capex in India provides Areva T&D India with significant visibility on order inflows and that the company is a top 3 player in India in the power and automation space. Areva T&D's peers BHEL and ABB are rated Low Risk. Our risk rating on the stock is based on a number of factors, namely industry-specific risks, financial risk and management risks. The upside risks that could cause shares to exceed our target price include the following: (a) better than expected order booking, (b) better than expected execution, and (c) better than expected margins. The key downside risks include the following: (a) increased competition, (b) slowdown in investments in generation, transmission and distribution, (c) slowdown in the industrial capex cycle, (d) substantial increase in input prices and (e) Employee retention.

ABB (India) (ABB.BO; Rs461.80; 3L)

Valuation

Our Rs448 target price for ABB is based on a target P/E multiple of 14x Dec 2009E. ABB's valuations are, in our view, largely pegged to the rate at which earnings grow. Our target P/E multiple is derived using the average PEG of 0.8 over the last 9 years and our expectations of 18% EPS CAGR over CY07-10E to arrive at a target P/E of 14x.

Risks

Our quantitative risk-rating system, which tracks 260-day historical share price volatility, assigns a Medium Risk rating to ABB India shares. However, we believe a Low Risk rating is more appropriate given that the strong power and industrial capex in India provides ABB with significant visibility on order inflows and ABB is India's market leader in the power and automation space. Our Low Risk rating is also in line with BHEL's. The key upside risks to our target price are: 1) better-than-expected order wins; 2) better-than-expected order execution; and 3) better-than-expected margins.

Larsen & Toubro (LART.BO; Rs660.30; 2L)

Valuation

We use a sum-of-the-parts (SOTP) methodology to value the L&T group, resulting in a target price of Rs697. Our target P/E multiple is set at 12x March 2010E, which is a 50% discount to its average P/E multiple over the last 4.5 years, warranted given the more challenging operating environment due to the global credit crisis. We also believe that the parent numbers do not capture the value inherent in the subsidiaries of L&T. We value L&T's subsidiaries at Rs107 with L&T Infotech at Rs21 (5x FY10E EPS, in-line with second-tier peers), L&T Finance at Rs18 (1.0x FY10E P/BV), and L&T IDPL at Rs33.

Risks


We rate L&T shares Low Risk, in line with our quantitative risk-rating system, and because L&T's order backlog of c.Rs630bn represents two years' sales and provides earnings visibility. Downside risks to our target price include: 1) attracting and retaining talent; 2) the E&C and electrical equipment businesses are sensitive to economic variables; 3) competitive pressures; and 4) L&T needs to keep abreast of technology trends to sustain valuations and earnings. Upside risks to our target price include: 1) better-than-expected order booking; 2) a better-than-expected execution rate; and 3) higher-than-expected EBITDA margins.


Appendix A-1

Analyst Certification

Each research analyst(s) principally responsible for the preparation and content of all or any identified portion of this research report hereby certifies that, with respect to each issuer or security or any identified portion of the report with respect to an issuer or security that the research analyst covers in this research report, all of the views expressed in this research report accurately reflect their personal views about those issuer(s) or securities. Each research analyst(s) also certify that no part of their compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this research report.

IMPORTANT DISCLOSURES





Citigroup Global Markets Inc. or its affiliates beneficially owns 1% or more of any class of common equity securities of Bharat Heavy, Larsen & Toubro. This position reflects information available as of the prior business day.

Within the past 12 months, Citigroup Global Markets Inc. or its affiliates has acted as manager or co-manager of an offering of securities of Areva T & D India, Bharat Heavy.

Citigroup Global Markets Inc. or its affiliates has received compensation for investment banking services provided within the past 12 months from ABB (India), Areva T & D India, Bharat Heavy, Larsen & Toubro.

Citigroup Global Markets Inc. or its affiliates expects to receive or intends to seek, within the next three months, compensation for investment banking services from Areva T & D India.

Citigroup Global Markets Inc. or an affiliate received compensation for products and services other than investment banking services from Thermax, ABB (India), Areva T & D India, Bharat Heavy, Larsen & Toubro in the past 12 months.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as investment banking client(s): ABB (India), Areva T & D India, Bharat Heavy, Larsen & Toubro.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, securitiesrelated: Thermax, ABB (India), Areva T & D India, Bharat Heavy, Larsen & Toubro.

Citigroup Global Markets Inc. currently has, or had within the past 12 months, the following as clients, and the services provided were non-investment-banking, nonsecurities-related: Thermax, ABB (India), Areva T & D India, Bharat Heavy, Larsen & Toubro.

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability, which includes revenues from, among other business units, the Private Client Division, Institutional Sales and Trading, and Investment Banking.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Investment Research product ("the Product"), please contact Citi Investment Research, 388 Greenwich Street, 29th Floor, New York, NY, 10013, Attention: Legal/Compliance. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at www.citigroupgeo.com. Private Client Division clients should refer to www.smithbarney.com/research. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Citi Investment Research Ratings Distribution

Data current as of 31 Dec 2008BuyHoldCiti Investment Research Global Fundamental Coverage46%37%% of companies in each rating category that are investment banking clients48%43%

Guide to Fundamental Research Investment Ratings:

Citi Investment Research's stock recommendations include a risk rating and an investment rating.

Risk ratings, which take into account both price volatility and fundamental criteria, are: Low (L), Medium (M), High (H), and Speculative (S).

Investment ratings are a function of Citi Investment Research's expectation of total return (forecast price appreciation and dividend yield within the next 12 months) and risk rating.

For securities in emerging markets (Asia Pacific, Emerging Europe/Middle East/Africa, and Latin America), investment ratings are:Buy (1) (expected total return of 15% or more for Low-Risk stocks, 20% or more for Medium-Risk stocks, 30% or more for High-Risk stocks, and 40% or more for Speculative stocks); Hold (2) (5%-15% for Low-Risk stocks, 10%-20% for Medium-Risk stocks, 15%-30% for High-Risk stocks, and 20%-40% for Speculative stocks); and Sell (3) (5% or less for Low-Risk stocks, 10% or less for Medium-Risk stocks, and 20% or less for Speculative stocks).

Investment ratings are determined by the ranges described above at the time of initiation of coverage, a change in investment and/or risk rating, or a change in target price (subject to limited management discretion). At other times, the expected total returns may fall outside of these ranges because of market price movements and/or other short-term volatility or trading patterns. Such interim deviations from specified ranges will be permitted but will become subject to review by Research Management. Your decision to buy or sell a security should be based upon your personal investment objectives and should be made only after evaluating the stock's expected performance and risk.

Guide to Corporate Bond Research Credit Opinions and Investment Ratings: Citi Investment Research's corporate bond research issuer publications include a fundamental credit opinion of Improving, Stable or Deteriorating and a complementary risk rating of Low (L), Medium (M), High (H) or Speculative (S) regarding the credit risk of the company featured in the report. The fundamental credit opinion reflects the CIR analyst's opinion of the direction of credit fundamentals of the issuer without respect to securities market vagaries. The fundamental credit opinion is not geared to, but should be viewed in the context of debt ratings issued by major public debt ratings companies such as Moody's Investors Service, Standard and Poor's, and Fitch Ratings. CBR risk ratings are approximately equivalent to the following matrix: Low Risk Triple A to Low Double A; Low to Medium Risk High Single A through High Triple B; Medium to High Risk Mid Triple B through High Double B; High to Speculative Risk Mid Double B and Below. The risk rating element illustrates the analyst's opinion of the relative likelihood of loss of principal when a fixed income security issued by a company is held to maturity, based upon both fundamental and market risk factors. Certain reports published by Citi Investment Research will also include investment ratings on specific issues of companies under coverage which have been assigned fundamental credit opinions and risk ratings. Investment ratings are a function of Citi Investment Research's expectations for total return, relative return (to publicly available Citigroup bond indices performance), and risk rating. These investment ratings are: Buy/Overweight the bond is expected to outperform the relevant Citigroup bond market sector index (Broad Investment Grade, High Yield Market or Emerging Market), performances of which are updated monthly and can be viewed at http://sd.ny.ssmb.com/ using the "Indexes" tab; Hold/Neutral Weight the bond is expected to perform in line with the relevant Citigroup bond

OTHER DISCLOSURES

The subject company's share price set out on the front page of this Product is quoted as at 29 January 2009 04:00 PM on the issuer's primary market.

Citigroup Global Markets Inc. and/or its affiliates has a significant financial interest in relation to ABB (India). (For an explanation of the determination of significant financial interest, please refer to the policy for managing conflicts of interest which can be found at www.citigroupgeo.com.)

Citigroup Global Markets Inc. or its affiliates beneficially owns 5% or more of any class of common equity securities of Larsen & Toubro.

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures

Sell

17%

38%

section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Investment Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Investment Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in Australia to wholesale clients through Citigroup Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992) and to retail clients through Citi Smith Barney Pty Ltd. (ABN 19 009 145 555 and AFSL No. 240813), Participants of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in Brazil by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of Canada by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. The Product is made available in France by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product may not be distributed to private clients in Germany. The Product is distributed in Germany by Citigroup Global Markets Deutschland AG & Co. KGaA, which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). Frankfurt am Main, Reuterweg 16, 60323 Frankfurt am Main. If the Product is made available in Hong Kong by, or on behalf of, Citigroup Global Markets Asia Ltd., it is attributable to Citigroup Global Markets Asia Ltd., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Product is made available in Hong Kong by The Citigroup Private Bank to its clients, it is attributable to Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. The Citigroup Private Bank and Citibank N.A. is regulated by the Hong Kong Monetary Authority. The Product is made available in India by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in Indonesia through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations, and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in Italy by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Foro Buonaparte 16, Milan, 20121, Italy. If the Product was prepared by Citi Investment Research and distributed in Japan by Nikko Citigroup Limited ("NCL"), it is being so distributed under license. If the Product was prepared by NCL and distributed by Nikko Cordial Securities Inc. or Citigroup Global Markets Inc. it is being so distributed under license. NCL is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. In the event that an error is found in an NCL research report, a revised version will be posted on Citi Investment Research's Global Equities Online (GEO) website. If you have questions regarding GEO, please call (81 3) 6270-3019 for help. The Product is made available in Korea by Citigroup Global Markets Korea Securities Ltd., which is regulated by Financial Supervisory Commission and the Financial Supervisory Service. Hungkuk Life Insurance Building, 226 Shinmunno 1-GA, Jongno-Gu, Seoul, 110-061. The Product is made available in Malaysia by Citigroup Global Markets Malaysia Sdn Bhd, which is regulated by Malaysia Securities Commission. Menara Citibank, 165 Jalan Ampang, Kuala Lumpur, 50450. The Product is made available in Mexico by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In New Zealand the Product is made available through Citigroup Global Markets New Zealand Ltd. (Company Number 604457), a Participant of the New Zealand Exchange Limited and regulated by the New Zealand Securities Commission. Level 19, Mobile on the Park, 157 Lambton Quay, Wellington. The Product is made available in Pakistan by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in Poland by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Bank Handlowy w Warszawie S.A. ul. Senatorska 16, 00-923 Warszawa. The Product is made available in the Russian Federation through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in Singapore through Citigroup Global Markets Singapore Pte. Ltd., a Capital Markets Services Licence holder, and regulated by Monetary Authority of Singapore. 1 Temasek Avenue, #39-02 Millenia Tower, Singapore 039192. The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Citigroup Global

Markets (Pty) Ltd. is incorporated in the Republic of South Africa (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in Spain by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gassef, 4th Floor, Madrid, 28006, Spain. The Product is made available in Taiwan through Citigroup Global Markets Taiwan Securities Company Ltd., which is regulated by Securities & Futures Bureau. No portion of the report may be reproduced or quoted in Taiwan by the press or any other person. No. 8 Manhattan Building, Hsin Yi Road, Section 5, Taipei 100, Taiwan. The Product is made available in Thailand through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F. 22/F and 29/F. 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in Turkey through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. The Product is made available in U.A.E. by Citigroup Global Markets Limited, which is authorised and regulated by the Dubai Financial Services Authority. DIFC, BIdg 2, Level 7, PO Box 506560, Dubai, UAE. The Product is made available in United Kingdom by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in United States by Citigroup Global Markets Inc, which is regulated by NASD, NYSE and the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority. Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Investment Research's Products can be found at www.citigroupgeo.com. Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations. The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted. Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product.

© 2009 Citigroup Global Markets Inc. (© Nikko Citigroup Limited, if this Product was prepared by it). Citi Investment Research is a division and service mark of Citigroup Global Markets Inc. and its affiliates and is used and registered throughout the world. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc and its affiliates and are used and registered throughout the world. Nikko is a registered trademark of Nikko Cordial Corporation. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure is prohibited by law and will result in prosecution. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST